Explore

Trendline Trendline
Kali Therapeutics to Present KT209 Antibody Data at EHA 2026

Kali Therapeutics to Present KT209 Antibody Data at EHA 2026

Kali Therapeutics to Present KT209 Antibody Data at EHA 2026
Trendline Trendline
Johnson Johnson Acquires Firefly Bio for $1 Billion to Enhance Cancer Treatment

Johnson Johnson Acquires Firefly Bio for $1 Billion to Enhance Cancer Treatment

Johnson Johnson Acquires Firefly Bio for $1 Billion to Enhance Cancer Treatment
Trendline Trendline
Antengene Unveils Preclinical Data on ATG-207 for Autoimmune Disease Treatment

Antengene Unveils Preclinical Data on ATG-207 for Autoimmune Disease Treatment

Antengene Unveils Preclinical Data on ATG-207 for Autoimmune Disease Treatment
Trendline Trendline
Antengene's ATG-207 Shows Potential in Autoimmune Disease Treatment

Antengene's ATG-207 Shows Potential in Autoimmune Disease Treatment

Antengene's ATG-207 Shows Potential in Autoimmune Disease Treatment
Trendline Trendline
Decoy Therapeutics CEO to Discuss Early Drug Development at hVIVO Event

Decoy Therapeutics CEO to Discuss Early Drug Development at hVIVO Event

Decoy Therapeutics CEO to Discuss Early Drug Development at hVIVO Event
Trendline Trendline
Tango Therapeutics and Revolution Medicines Achieve 92% Response in Pancreatic Cancer Trial

Tango Therapeutics and Revolution Medicines Achieve 92% Response in Pancreatic Cancer Trial

Tango Therapeutics and Revolution Medicines Achieve 92% Response in Pancreatic Cancer Trial
Trendline Trendline
Lifordi Immunotherapeutics Unveils Promising Phase 1 Data for Rheumatoid Arthritis Treatment

Lifordi Immunotherapeutics Unveils Promising Phase 1 Data for Rheumatoid Arthritis Treatment

Lifordi Immunotherapeutics Unveils Promising Phase 1 Data for Rheumatoid Arthritis Treatment
Trendline Trendline
Diakonos Oncology Presents Promising Data on DOC1021 for Glioblastoma and Melanoma at ASCO 2026

Diakonos Oncology Presents Promising Data on DOC1021 for Glioblastoma and Melanoma at ASCO 2026

Diakonos Oncology Presents Promising Data on DOC1021 for Glioblastoma and Melanoma at ASCO 2026
Trendline Trendline
Vycellix to Present Progress on Universal Cell Cancer Therapy at Key International Meetings

Vycellix to Present Progress on Universal Cell Cancer Therapy at Key International Meetings

Vycellix to Present Progress on Universal Cell Cancer Therapy at Key International Meetings
Trendline Trendline
Vycellix Announces Progress in Universal Cell Cancer Therapy at Upcoming Meetings

Vycellix Announces Progress in Universal Cell Cancer Therapy at Upcoming Meetings

Vycellix Announces Progress in Universal Cell Cancer Therapy at Upcoming Meetings
Trendline Trendline
Onchilles Pharma Begins Phase 1/2 Trial of N17350 for Advanced Solid Tumors

Onchilles Pharma Begins Phase 1/2 Trial of N17350 for Advanced Solid Tumors

Onchilles Pharma Begins Phase 1/2 Trial of N17350 for Advanced Solid Tumors
Trendline Trendline
Onchilles Pharma Begins Clinical Trial for Cancer Treatment N17350

Onchilles Pharma Begins Clinical Trial for Cancer Treatment N17350

Onchilles Pharma Begins Clinical Trial for Cancer Treatment N17350